SCHEMBL823692

SCHEMBL823692

CC(=O)Oc1cc(F)c(F)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.52
CYP4A11 Q02928 2/20 0.52
LMNA P02545 3/20 0.45
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
KDM4E B2RXH2 3/20 0.44
CYP3A4 P08684 2/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
TTR P02766 1/20 0.44
TP53 P04637 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
BACE1 P56817 1/20 0.43
MAOB P27338 1/20 0.42
POLB P06746 1/20 0.41
PKM P14618 1/20 0.41
CYP19A1 P11511 1/20 0.41
ACHE P22303 2/20 0.40
ELANE P08246 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12906518 0.89 CYP4F2 (0.44) CYP4F2CYP4A11LMNACES2CES1
SCHEMBL24445858 0.88 CYP3A4 (0.47) CYP4F2CYP4A11LMNACES2CES1
SCHEMBL17355735 0.84 CYP4F2 (0.50) CYP4F2CYP4A11LMNAKDM4ECYP3A4
SCHEMBL16322544 0.84 CYP4F2 (0.50) CYP4F2CYP4A11LMNAKDM4ECYP3A4
SCHEMBL21810571 0.81 CES2 (0.48) CYP4F2CYP4A11CES2CES1MAPT
SCHEMBL31403415 0.81 CYP4F2 (0.47) CYP4F2CYP4A11LMNAKDM4ECYP3A4
SCHEMBL21503687 0.81 ELANE (0.48) CYP4F2CYP4A11CES2CES1MAOB
SCHEMBL3238033 0.81 CYP4F2 (0.47) CYP4F2CYP4A11LMNAKDM4ECYP3A4
SCHEMBL16604314 0.80 LMNA (0.42) LMNAKDM4ECYP3A4MAPTBACE1
SCHEMBL1257132 0.80 CYP4F2 (0.50) CYP4F2CYP4A11LMNAKDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10483466-B2 P-doping cross-linking of organic hole transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2019-11-19 US claimed
EP-3114715-B1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS SIEMENS AG (DE) 2019-10-30 EP claimed
US-20180198069-A1 P-Doping Cross-Linking Of Organic Hole Transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2018-07-12 US claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US claimed
WO-2025054260-A1 INHIBITORS OF MEK KINASE KINNATE BIOPHARMA INC. (US) 2025-03-13 WO disclosed
US-10483466-B2 P-doping cross-linking of organic hole transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2019-11-19 US disclosed
US-20180240975-A1 Bi-Nuclear Main Group Metal Phosphorescent Emitter SIEMENS AKTIENGESELLSCHAFT (DE) 2018-08-23 US disclosed
US-20180198069-A1 P-Doping Cross-Linking Of Organic Hole Transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2018-07-12 US disclosed
EP-3114190-B1 BI-NUCLEAR MAIN GROUP METAL PHOSPHORESCENT EMITTER SIEMENS AG (DE) 2018-06-06 EP disclosed
CN-107667439-A Formulations comprising organic semiconductors and metal complexes 默克专利有限公司 2018-02-06 CN disclosed
CN-107003460-A Polymeric materials having negative photoelastic constants 罗门哈斯电子材料有限责任公司 2017-08-01 CN disclosed
EP-3114190-A1 BI-NUCLEAR MAIN GROUP METAL PHOSPHORESCENT EMITTER Siemens Aktiengesellschaft (DE) 2017-01-11 EP disclosed
US-20070272003-A1 2-(2-{2-[2-(2-{2-[2-(11-mercaptoyldisulfanyl-undecyloxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy} acetic acid pentafluorophenyl ester; poly(ethylene oxide) groups resist nonspecific adsorption and enhance the specific affinity interactions IMEC (BE) 2007-11-29 US disclosed
EP-1798250-A2 Molecules suitable for binding to a metal layer for covalently immobilizing biomolecules INTERUNIVERSITAIR MICROELEKTRONICA CENTRUM vzw (IMEC) (BE) 2007-06-20 EP disclosed
CN-1616432-A Compound,its use and pharmaceutical compositions comprising same ELAN PHARM INC (US) 2005-05-18 CN disclosed
CN-1171878-C Compounds, their use and pharmaceutical compositions containing them ������˹ҩƷ��˾ 2004-10-20 CN disclosed
CN-1242007-A Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising such compounds, and methods of inhibiting beta amyloid peptide release and/or its synthesis using such compounds ELAND PHARMACEUTICAL CORP (US) 2000-01-19 CN disclosed
EP-0387032-B1 TRIFLUOROBENZENE DERIVATIVES AND LIQUID CRYSTAL COMPOSITIONS CONTAINING THE SAME CHISSO CORP (JP) 1993-06-16 EP disclosed
US-5032313-A Trifluorobenzene derivative and liquid crystal composition containing the same CHISSO CORPORATION (JP) 1991-07-16 US disclosed
EP-0387032-A1 Trifluorobenzene derivatives and liquid crystal compositions containing the same Chisso Corporation (JP) 1990-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180240975-A1 Bi-Nuclear Main Group Metal Phosphorescent Emitter FOXM1, NUCB2, L3MBTL3 CYP4F2 1525/4885CYP4A11 4416/4885LMNA 151/4885
US-20070272003-A1 2-(2-{2-[2-(2-{2-[2-(11-mercaptoyldisulfanyl-undecyloxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy} acetic acid pentafluorophenyl ester; poly(ethylene oxide) groups resist nonspecific adsorption and enhance the specific affinity interactions EBPL, AEBP2, NAPA CYP4F2 1008/4885CYP4A11 4322/4885LMNA 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.